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Abstract
Recently Byrski et al. reported the first-ever breast cancer (BC) study, which specifically selected
BRCA1-carriers for the neoadjuvant treatment and used monotherapy by cisplatin instead of
conventional schemes. Although the TNM staging of the recruited patients was apparently more
favorable than in most of published neoadjuvant trials, the results of Byrski et al. clearly outperform
any historical data. Indeed, 9 of 10 BRCA1-associated BC demonstrated complete pathological
response to the cisplatin treatment, i.e. these women have good chances to be ultimately cured
from the cancer disease. High sensitivity of BRCA1-related tumors to platinating agents has been
discussed for years, but it took almost a decade to translate convincing laboratory findings into first
clinical observations. With increasing stratification of tumor disease entities for molecular subtypes
and rapidly growing armamentarium of cancer drugs, it is getting technically and ethically impossible
to subject all promising treatment options to the large randomized prospective clinical trials.
Therefore, alternative approaches for initial drugs evaluation are highly required, and one of the
choices is to extract maximum benefit from already available collections of biological material and
medical charts. For example, many thousands of BC patients around the world have already been
subjected to second- or third-line therapy with platinum agents, but the association between BRCA
status and response to the treatment has not been systematically evaluated in these women. While
potential biases of retrospective studies are widely acknowledged, it is frequently ignored that the
use of archival collections may provide preliminary answers for long-standing questions within days
instead of years. However, even elegantly-designed, small-sized, hypothesis-generating
retrospective studies may require multicenter efforts and somewhat cumbersome logistics, that
may explain the surprising lack of historical data on the platinum-based treatment of BC in BRCA1
carriers.
Introduction
On July 23, 2008, Breast Cancer Research and Treatment
journal released an electronic publication ahead of print
of the first-ever breast cancer (BC) study, which specifi-
cally selected BRCA1-carriers for the neoadjuvant treat-
ment and used monotherapy by cisplatin instead of
conventional schemes [1]. The results of the this explora-
tory trial are absolutely fascinating: 9 out of 10 patients
experienced complete pathologic tumor response, so
these women are expected to be relapse-free for a pro-
longed period of time or, hopefully, forever.
Discussion
The limitation of the study of Byrski et al. [1] is an unusu-
ally favorable TNM staging of the treated population: 5
out of 10 females had tumor size below 2 cm, and 7 were
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lymph node negative. In comparison, retrospective analy-
sis of Chappuis et al. [2], in which 4 out of 9 evaluable
BRCA1 carriers demonstrated complete pathologic tumor
response to anthracycline-based neoadjuvant therapy,
included only 1 and 3 patients with T1 and N0 status,
respectively. However, even upon some adjustment for
the disease stage and moderate study size, the results of
Byrski et al. [1] clearly outperform all known BC neoadju-
vant trials.
Evidence for increased sensitivity of BRCA1-associated
tumors to some chemotherapeutic agents started to accu-
mulate nearly a decade ago, and the use of platinating
compounds specifically for hereditary breast or ovarian
cancers is being discussed in the literature for several years
[see [3-9] and references therein]. Why it took so long to
translate fairly convincing laboratory findings into clinical
observations? First of all, relatively high efficacy of tradi-
tional drug combinations makes it difficult to justify a BC
trial for a novel agent, unless heavily pretreated patients
with advanced metastatic disease are involved. However,
these women are less likely to demonstrate evident
response even to a highly specific therapeutic interven-
tion, due to acquired multidrug tumor resistance and gen-
eral exhaustion of the body resources. In addition,
selection of BRCA1 carriers for the trial possesses a prob-
lem because of rarity of BRCA1-associated BC (less than
5% of unselected BC patients) and high cost of BRCA1
testing.
These difficulties are reflected by ongoing randomized
trial on BRCA1 and BRCA2 carriers, whose breast cancer
disease progressed after adjuvant or palliative anthracy-
cline-based therapy http://www.geneticbreastcancer
trial.usilu.net/. The standard option for anthracycline-
resistant BC is the use of taxanes. In the above trial of
BRCA-associated BC, patients are randomized to receive
either docetaxel (standard arm) or carboplatin (experi-
mental arm). The study was launched in April, 2006 http:/
/www.geneticbreastcancertrial.usilu.net/newsletter.asp
and is expected to complete the recruitment by October,
2009. The planned study size is 148 subjects; by the year
2008, 15 patients have been successfully recruited
http:www.geneticbreastcancertrial.usilu.net/currentsta
tus.htm.
Byrski et al. [1] have chosen more decisive approach, ben-
efiting from some favorable circumstances in Poland, e.g.
well-established infrastructure for hereditary cancer diag-
nosis, large number of oncological patients undergoing
routine DNA testing, and high impact of BRCA1 founder
mutations in BC morbidity. Based on sound preclinical
evidence for increased sensitivity of BRCA1-deficient
breast cancer cells to platinating agents, this Polish-Cana-
dian research team has taken a risk of recruiting poten-
tially operable and yet chemonaive breast cancer patients
for the study. Furthermore, while most of neoadjuvant
schemes for BC treatment are based on combinations of
several drugs, Byrski et al [1] left no room for ambiguous
interpretation by deciding to use cisplatin as a mono-
therapy. Although long-term outcomes for these patients,
particularly the response to the treatments in case of
tumor relapse, remain to be seen, the study of Byrski et al
[1] has to be considered as the first long-awaited clinical
argument for the preferential use of platinating agents in
BRCA1 carriers.
As for all human studies, the designs of the above 2 trials
may be a subject of debate. One would argue, that the
described randomized trial for carboplatin versus
docetaxel is designed with perfect respect of the current
treatment standards and is expected to provide highly
conclusive data sets, but it is overly conservative and
therefore it will take too long for the final results of this
trial to become available. In contrast, Byrski et al. [1]
offered an experimental treatment to those patients, who
had a relatively good chances to be cured by already exist-
ing approaches; perhaps, the design of this neoadjuvant
study could become a subject of harsh criticism if cisplatin
failed to induce spectacular tumor responses in BRCA1
carriers.
With increasing stratification of tumor disease entities for
molecular subtypes and rapidly growing armamentarium
of cancer drugs, it is naïve to expect that all promising
treatment options will be subjected to prospective rand-
omized trials. Furthermore, the pipeline for novel smart
antitumor molecules appears to work faster than the one
for clinical trials. For example, the results of the rand-
omized trial on the use of platinum compounds against
BRCA-associated BC are unlikely to be obtained before
the end of this decade; by that time, the data on PARP
inhibitors will probably become available as well [9], and
the latter drugs could have better chances to enter clinical
settings because of more favorable safety profile [10]. In
other words, platinum compounds may become outdated
just after passing the test.
Therefore, alternative approaches for initial drugs evalua-
tion are highly required, and one of the choices is to use
retrospective biological material and medical charts [11].
For example, many thousands of BC patients around the
world have already been subjected to second- or third-line
therapy with platinum agents, but BRCA status has not
been systematically evaluated in these women. If we
hypothesize the advantage of platinum-based treatment
for BRCA carriers, the most straightforward approach
would be to collect archival material from responders,
and to examine if the frequency of BRCA mutations is ele-
vated in this rare category of patients. Interestingly, simi-Publish with BioMed Central    and   every 
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lar strategy was recently applied by Wysocki et al. [12],
who limited BRCA1 analysis by BC patients with resist-
ance to neoadjuvant docetaxel, and confirmed earlier clin-
ical observations on the poor response of BRCA1-
associated BC to taxanes [13]. Instead of selection of
highly demonstrative categories of patients, one may also
rely on communities with founder effect, where the anal-
ysis of BRCA status is cheap and high number of BC
patients can be DNA-tested [14].
Conclusion
While potential biases of retrospective studies are widely
acknowledged, it is frequently ignored that the use of
archival collections may provide preliminary answers for
long-standing questions within days instead of years.
However, even elegantly-designed, small-sized, hypothe-
sis-generating retrospective studies may require multi-
center efforts and somewhat cumbersome logistics, that
may explain the surprising lack of historical data on the
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